Background Uterine leiomyomas are the most common neoplasm affecting women and
frequently cause heavy menstrual bleeding and pain. Gonadotropin-releasing hormone …

OBJECTIVE: To investigate the safety and efficacy of elagolix, an oral gonadotropin-
releasing hormone antagonist, with hormonal add-back therapy for up to 12 months in …

Objective To evaluate the effect of relugolix combination therapy (relugolix CT; 40 mg
relugolix, 1 mg estradiol, and 0.5 mg norethisterone acetate) for up to 2 years in the SPIRIT …

Introduction Uterine fibroids, the most prevalent benign tumors among reproductive-age
women, pose treatment challenges that range from surgical interventions to medical …

Background Uterine fibroids constitute a significant health problem in the United States,
affecting upward of 11 million people. Objective Characterize the literature regarding the …

Objective: To assess the psychometric performance of the 4 week recall version of the
Uterine Fibroid Symptom and Health-related Quality of Life Questionnaire (UFS-QoL), a …

Objective: To summarize the literature describing the impact of uterine fibroids on health-
related quality of life (HRQOL), the measures used to assess HRQOL, and related areas for …

Elagolix, a gonadotropin-releasing hormone antagonist, plus hormonal add-back therapy
reduced heavy menstrual bleeding from uterine leiomyomas during up to 12 months of …

OBJECTIVE: To quantify the burden of uterine fibroids (UF) on health-related quality of life
(HRQOL) and work productivity in a general population of women. STUDY DESIGN: Women …

Background Heavy menstrual bleeding (HMB) is a common clinical finding in patients with
uterine leiomyomas that can negatively impact their quality of life. Recently, a novel oral …